Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

PAGln in Gut Microbiome Represents Potential Link to Lethal Prostate Cancer

February 25th 2022

Nima Sharifi, MD, PLCO, discusses the results of the prostate cancer cohort in the PLCO trial and how PAGln could be linked to patients eventually diagnosed with lethal prostate cancer.

Bavdegalutamide Showcases Early Activity in Metastatic Castration-Resistant Prostate Cancer

February 24th 2022

The novel androgen receptor PROTAC degrader, bavdegalutamide, was found to be clinically active and tolerable with manageable adverse effects in patients with metastatic castration-resistant prostate cancer.

Niraparib Demonstrates Antitumor Activity in Heavily Pretreated mCRPC With BRCA Mutations

February 23rd 2022

The PARP inhibitor niraparib elicited a meaningful overall response rate in patients with heavily pretreated metastatic castration-resistant prostate cancer and DNA repair gene defects, particularly those with BRCA alterations.

Dr. Lowentritt on a Real-World Analysis of Apalutamide and Enzalutamide in mCSPC

February 23rd 2022

Benjamin H. Lowentritt, MD, FACS, discusses the real-world analysis of apalutamide and enzalutamide in metastatic castration-sensitive prostate cancer.

Darolutamide Demonstrates Strong Safety Profile in mCRPC after Long-Term Analyses

February 18th 2022

Darolutamide produced a well-tolerated safety profile in patients with metastatic castration-resistant prostate cancer, according to pooled data from long-term analyses of 3 trials.

18F-rhPSMA-7.3 Imaging Favorable Detection Rates in Men with Recurrent Prostate Cancer

February 18th 2022

The utilization of 18F-rhPSMA-7.3 imaging displayed a clinically meaningful correct detection rate.

Darolutamide Maintains Efficacy in Patients with Comorbidities, Concomitant Medications in Nonmetastatic CRPC

February 18th 2022

The androgen receptor inhibitor darolutamide demonstrated continued efficacy and safety in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who have comorbidities or concomitant medications

Continuous Enzalutamide After Progression Improves PFS in Patients with mCRPC

February 18th 2022

Continuous enzalutamide plus docetaxel and prednisone elicited progression-free survival improvement vs placebo with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer who had previously progressed on enzalutamide alone

Darolutamide Plus ADT Boosts OS in Metastatic Castration-Sensitive Prostate Cancer

February 18th 2022

The addition of darolutamide to androgen deprivation therapy and docetaxel generated better overall survival vs placebo with ADT and docetaxel in patients with metastatic castration-sensitive prostate cancer.

Frontline Niraparib Plus Abiraterone Improves rPFS in HRR Gene–Altered mCRPC

February 17th 2022

The combination of niraparib and abiraterone acetate and prednisone led to a significant improvement in radiographic progression-free survival vs placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.

Olaparib/Abiraterone Combo Significantly Improves Radiographic PFS in mCRPC

February 17th 2022

Olaparib in combination with abiraterone acetate led to a 34% reduction in the risk of radiographic disease progression or death compared with placebo and abiraterone as a first-line treatment for patients with metastatic castration-resistant prostate cancer, according to results of the phase 3 PROpel trial.

Deep PSA Response Is Associated with Positive Wellbeing Scores in Advanced Prostate Cancer

February 17th 2022

Treatment with apalutamide, an androgen receptor inhibitor, was associated with a deep PSA response leading to beneficial outcomes in patient-related end points.

Apalutamide Outperforms Enzalutamide in mCSPC in Real-World Analysis

February 17th 2022

A greater portion of patients with metastatic castration-sensitive prostate cancer achieved an early and deep prostate-specific antigen reduction from baseline of 90% or more when treated with apalutamide compared with enzalutamide.

Dr. Saad on the Efficacy of First-Line Olaparib Plus Abiraterone in mCRPC

February 17th 2022

Fred Saad, MD, FRCS, discusses the efficacy of olaparib plus abiraterone acetate as first-line treatment in metastatic castration-resistant prostate cancer.

Dr. Merseburger on the Efficacy of Continuing Enzalutamide in mCRPC

February 17th 2022

Axel Merseburger, MD, PhD, discusses results from the phase 3b PRESIDE trial in metastatic castration-resistant prostate cancer.

Dr. Armstrong on Findings From a Post-Hoc Analysis of the ARCHES Trial in mHSPC

February 17th 2022

Andrew J. Armstrong, MD, MSc, discusses findings from a post-hoc analysis of the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.

Dr. Tewari on the Factors to Consider for Robotic Radical Prostatectomy in Prostate Cancer

February 16th 2022

Ashutosh K. Tewari, MD, discusses the factors to consider when deciding on a robotic radical prostatectomy for a patient with prostate cancer.

FDA Grants Breakthrough Status to TriNetra-Prostate Blood Test to Detect Early-Stage Prostate Cancer

February 15th 2022

The FDA has granted a breakthrough device designation to the TriNetra-Prostate blood test for use in the detection of early-stage prostate cancer.

Dr. Sharifi on Methodologies Utilized to Evaluate Link Between Gut Microbiome and Fatal Prostate Cancer

February 14th 2022

Nima Sharifi, MD, director, discusses the methodologies utilized when evaluating the correlation between gut microbiome and fatal prostate cancer.

Molecular Differences Contribute to Disparity Between Black and White Patients with Prostate Cancer

February 10th 2022

Dhyan Chandra, PhD, discusses recent findings relating to low levels of cytochrome C in Black men with prostate cancer, plus plans for future research on this topic.